Advertisement
Screener

Citadel Advisors LLC Historic Quarter Change: USA Bonds: Other Debt, Sold Out, 2019 Q3

CITADEL ADVISORS LLC historic quarter change: USA Bonds: Other Debt, Sold out

In other debt filed by principal amount (debentures, bonds) (listed in the US), over 51 quarters from 2013-06-30 to 2026-03-31, CITADEL ADVISORS LLC opened 884 positions, added to 1,270, reduced 1,104 and sold out of 996.

  • Q3 2019: Stock HERBALIFE LTD; Country of operation —; Class Bond; Principal before $35,600,000.
  • Q3 2019: Stock REPLIGEN CORP; Country of operation —; Class Bond; Principal before $12,623,000.
  • Q3 2019: Stock PDL BIOPHARMA INC; Country of operation —; Class Bond; Principal before $31,733,000.
  • Q3 2019: Stock LIGAND PHARMACEUTICALS INC; Country of operation —; Class Bond; Principal before $17,000,000.

Each consecutive pair of Form 13F-HR filings compared (SEC CIK 1423053), 51 quarters: Q1 2026 (2025-12-31 to 2026-03-31, filed 2026-05-15); Q4 2025 (2025-09-30 to 2025-12-31, filed 2026-02-17); Q3 2025 (2025-06-30 to 2025-09-30, filed 2025-11-14); Q2 2025 (2025-03-31 to 2025-06-30, filed 2025-08-14); Q1 2025 (2024-12-31 to 2025-03-31, filed 2025-05-15); Q4 2024 (2024-09-30 to 2024-12-31, filed 2025-02-14); Q3 2024 (2024-06-30 to 2024-09-30, filed 2024-11-14); Q2 2024 (2024-03-31 to 2024-06-30, filed 2024-08-14); Q1 2024 (2023-12-31 to 2024-03-31, filed 2024-05-15); Q4 2023 (2023-09-30 to 2023-12-31, filed 2024-02-14); Q3 2023 (2023-06-30 to 2023-09-30, filed 2023-11-14); Q2 2023 (2023-03-31 to 2023-06-30, filed 2023-08-14); Q1 2023 (2022-12-31 to 2023-03-31, filed 2023-05-15); Q4 2022 (2022-09-30 to 2022-12-31, filed 2023-02-14); Q3 2022 (2022-06-30 to 2022-09-30, filed 2022-11-14); Q2 2022 (2022-03-31 to 2022-06-30, filed 2022-08-15); Q1 2022 (2021-12-31 to 2022-03-31, filed 2022-05-16); Q4 2021 (2021-09-30 to 2021-12-31, filed 2022-02-14); Q3 2021 (2021-06-30 to 2021-09-30, filed 2021-11-15); Q2 2021 (2021-03-31 to 2021-06-30, filed 2021-08-16); Q1 2021 (2020-12-31 to 2021-03-31, filed 2021-05-17); Q4 2020 (2020-09-30 to 2020-12-31, filed 2021-02-16); Q3 2020 (2020-06-30 to 2020-09-30, filed 2020-11-16); Q2 2020 (2020-03-31 to 2020-06-30, filed 2020-08-14); Q1 2020 (2019-12-31 to 2020-03-31, filed 2020-05-15); Q4 2019 (2019-09-30 to 2019-12-31, filed 2020-02-14); Q3 2019 (2019-06-30 to 2019-09-30, filed 2019-11-14); Q2 2019 (2019-03-31 to 2019-06-30, filed 2019-08-14); Q1 2019 (2018-12-31 to 2019-03-31, filed 2019-05-15); Q4 2018 (2018-09-30 to 2018-12-31, filed 2019-02-14); Q3 2018 (2018-06-30 to 2018-09-30, filed 2018-11-13); Q2 2018 (2018-03-31 to 2018-06-30, filed 2018-08-10); Q1 2018 (2017-12-31 to 2018-03-31, filed 2018-05-11); Q4 2017 (2017-09-30 to 2017-12-31, filed 2018-02-09); Q3 2017 (2017-06-30 to 2017-09-30, filed 2017-11-09); Q2 2017 (2017-03-31 to 2017-06-30, filed 2017-08-11); Q1 2017 (2016-12-31 to 2017-03-31, filed 2017-05-12); Q4 2016 (2016-09-30 to 2016-12-31, filed 2017-02-10); Q3 2016 (2016-06-30 to 2016-09-30, filed 2016-11-10); Q2 2016 (2016-03-31 to 2016-06-30, filed 2016-08-12); Q1 2016 (2015-12-31 to 2016-03-31, filed 2016-05-13); Q4 2015 (2015-09-30 to 2015-12-31, filed 2016-02-12); Q3 2015 (2015-06-30 to 2015-09-30, filed 2015-11-16); Q2 2015 (2015-03-31 to 2015-06-30, filed 2015-08-14); Q1 2015 (2014-12-31 to 2015-03-31, filed 2015-05-15); Q4 2014 (2014-09-30 to 2014-12-31, filed 2015-02-18); Q3 2014 (2014-06-30 to 2014-09-30, filed 2014-11-14); Q2 2014 (2014-03-31 to 2014-06-30, filed 2014-08-14); Q1 2014 (2013-12-31 to 2014-03-31, filed 2014-05-15); Q4 2013 (2013-09-30 to 2013-12-31, filed 2014-02-14); Q3 2013 (2013-06-30 to 2013-09-30, filed 2013-11-14). Rows for the same security, class and put/call are added together. Value change is the filed value at each quarter end, so it includes the price move. Only the filings held here are compared; the firm's 13F-HR filings go back to the quarter ended 2009-12-31.

QuarterStockCountry of operationClassPrincipal beforePrincipal afterShare changeValue beforeValue afterValue changeFiled
Q3 2019HERBALIFE LTD
CUSIP 42703MAB9
—Bond$35,600,000$0-35,600,000$36,650$0-$36,6502019-11-14
Q3 2019REPLIGEN CORP
CUSIP 759916AA7
—Bond$12,623,000$0-12,623,000$34,239$0-$34,2392019-11-14
Q3 2019PDL BIOPHARMA INC
CUSIP 69329YAG9
—Bond$31,733,000$0-31,733,000$33,394$0-$33,3942019-11-14
Q3 2019LIGAND PHARMACEUTICALS INC
CUSIP 53220KAD0
—Bond$17,000,000$0-17,000,000$25,702$0-$25,7022019-11-14
Q3 2019ASSERTIO THERAPEUTICS INC
CUSIP 249908AA2
—Bond$25,498,000$0-25,498,000$18,483$0-$18,4832019-11-14
Q3 2019UNISYS CORP
CUSIP 909214BS6
—Bond$14,343,000$0-14,343,000$17,581$0-$17,5812019-11-14
Q3 2019MOLINA HEALTHCARE INC
CUSIP 60855RAC4
—Bond$5,000,000$0-5,000,000$17,436$0-$17,4362019-11-14
Q3 2019HURON CONSULTING GROUP INC
CUSIP 447462AB8
—Bond$16,500,000$0-16,500,000$16,393$0-$16,3932019-11-14
Q3 2019ZILLOW GROUP INC
CUSIP 98954MAC5
—Bond$11,000,000$0-11,000,000$10,847$0-$10,8472019-11-14
Q3 2019ARRAY BIOPHARMA INC
CUSIP 04269XAB1
—Bond$3,000,000$0-3,000,000$9,129$0-$9,1292019-11-14
Q3 2019ENSCO JERSEY FIN LTD
CUSIP 29359WAB1
—Bond$7,500,000$0-7,500,000$5,926$0-$5,9262019-11-14
Q3 2019VIAVI SOLUTIONS INC
CUSIP 925550AE5
—Bond$4,834,000$0-4,834,000$5,593$0-$5,5932019-11-14
Q3 2019CLOVIS ONCOLOGY INC
CUSIP 189464AB6
—Bond$6,000,000$0-6,000,000$5,338$0-$5,3382019-11-14
Q3 2019SCORPIO TANKERS INC
CUSIP 80918TAB5
—Bond$5,000,000$0-5,000,000$5,201$0-$5,2012019-11-14
Q3 2019WESTERN ASSET MTG CAP CORP
CUSIP 95790DAA3
—Bond$4,000,000$0-4,000,000$3,960$0-$3,9602019-11-14
Q3 2019CTRIP COM INTL LTD
CUSIP 22943FAF7
—Bond$3,000,000$0-3,000,000$2,965$0-$2,9652019-11-14
Q3 2019ZILLOW GROUP INC
CUSIP 98954MAB7
—Bond$2,500,000$0-2,500,000$2,835$0-$2,8352019-11-14
Q3 2019CORENERGY INFRASTRUCTURE TR
CUSIP 21870UAA4
—Bond$1,500,000$0-1,500,000$1,807$0-$1,8072019-11-14
Q3 2019HORNBECK OFFSHORE SVCS INC N
CUSIP 440543AN6
—Bond$1,941,000$0-1,941,000$1,718$0-$1,7182019-11-14
Q3 2019TEVA PHARMACEUTICAL FIN LLC
CUSIP 88163VAE9
—Bond$1,000,000$0-1,000,000$918$0-$9182019-11-14